Tumor volume analyses demonstrated that single anti‐PD‐1 mAbs showed moderate therapeutic effects; but when anti‐MARCO antibody was combined with anti‐PD‐1 therapy treatment, it might dramatically slow tumor development (Figure 7B). Here, MARCO is linked to neoplasm.